Zymeworks Inc. (ZYME)
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $106.0M
- Net income
- -$81.1M
- Total assets
- $346.5M
- Market cap
- $1.7B
- Operating margin
- -87.3%
- Net margin
- -76.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $106.0M
- Operating expenses
- $198.5M
- Operating income
- -$92.5M
- Income tax
- $1.4M
- Net income
- -$81.1M
- EPS (basic)
- $-1.08
- EPS (diluted)
- $-1.08
Balance sheet
- Total assets
- $346.5M
- Current assets
- $248.8M
- Total liabilities
- $78.0M
- Current liabilities
- $42.3M
- Shareholders’ equity
- $268.5M
Cash flow
- Operating cash flow
- -$33.0M
- Investing cash flow
- $26.7M
- Financing cash flow
- -$18.6M
- Net cash flow
- -$24.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.7B
- EPS (diluted)
- $-1.08
- Shares outstanding
- 58.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 28, 2017
Zymeworks Inc. (ZYME) Stock Price
- Reported a net loss of $81.1M in FY2025.
- Revenue grew 297% from FY2021 to FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Zymeworks Inc..
Write a review
News about Zymeworks Inc.
News & sentiment via Polygon.io
Zymeworks Inc.: frequently asked questions
Is Zymeworks Inc. an American company?
Zymeworks Inc. is a US-based company headquartered in Middletown, Delaware, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Zymeworks Inc. headquartered?
Zymeworks Inc. is headquartered in Middletown, Delaware, United States.
Is Zymeworks Inc. publicly traded?
Yes — Zymeworks Inc. is a publicly traded company. Its stock trades under the ticker symbol ZYME on the NASDAQ.
What does Zymeworks Inc. do?
Zymeworks Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Zymeworks Inc. founded?
Zymeworks Inc. was founded in 2003.
